A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
about
Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacementPrevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesClinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indicationsAnticoagulant therapy in pediatricsDabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisonsProtocol in managing oral surgical patients taking dabigatranNew oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsAnithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapyRivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitorEvaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulationVenous thromboembolism: classification, risk factors, diagnosis, and management.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.Rivaroxaban as an Antithrombotic Agent in a Patient With ST-Segment Elevation Myocardial Infarction and Left Ventricular Thrombus: A Case Report.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyApixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.Post-operative thromboprophylaxis: new oral thrombin and factor X inhibitors and their place in clinical practice.Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorA randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxabanBody weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update.Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.New options in anticoagulation for the prevention of venous thromboembolism and stroke.Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery.Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery.Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixabanRisk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin.Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trialsInvestigational treatments of venous thromboembolism.Venous thromboembolism prevention in cancer patients: the search for common antecedents.New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban.Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding.Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry.An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.Rivaroxaban: a novel, oral, direct factor Xa inhibitor.Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.New drugs and devices from 2011 - 2012 that might change your practice.Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.
P2860
Q24235993-49D31741-A7D1-4168-A50E-18866CFCFF03Q24632872-2ABCA140-6207-4E50-B1C6-4A7F9E43624FQ26828817-88552B79-3194-4F43-9D1D-17827979D71CQ26829750-6425FA22-606F-4E1B-83CA-40682DB3B833Q26995635-5A366E6C-B091-4D98-AD1A-19C04B0CE176Q27006890-F836999D-0462-4BC1-8080-40E50EF573EFQ28080616-8C811664-1112-4F3D-8D54-CB11A032FA27Q28220433-D1166113-B0BB-4C91-A28F-FBFF2D2DDF1CQ28250157-CA36CA7C-A60D-42EF-8974-0BC74C11E289Q28477868-3A18B825-2CE6-436C-9FC8-100573445517Q30472938-198FD584-F419-4FB1-82C0-6C46AEBE60F5Q33389966-E64CD1BF-EF2B-4AD9-9AA0-34BBF6FBA2A1Q33402042-FF8D1B71-1E44-40B1-BD74-38080B1A16C1Q33693257-48083FB4-3A49-4202-8CA9-5E138F5853D1Q33891915-0AEDDE34-F9E3-4142-B071-5FDBAD460B95Q34088870-B70A1350-5B8E-46DA-8739-365CD49239F1Q34175551-7711C9CF-DA31-4CEA-BE0A-FD0C59AE44A2Q34381344-42FE2A2E-BDD2-4DB3-BF1B-8F44B6C498BBQ34531991-B862327D-AE52-4317-9C2A-DB28C7F75EBEQ34605304-D8B93D11-86D6-4DE8-A253-42A659C09E96Q34622654-AE493179-5160-4BC1-836B-13500F2C7520Q34627624-B5E186F2-54AF-4F8E-A422-87FC787D6BFBQ34635335-2689FCAB-CBED-476A-993E-4FC8EF9C249DQ34906214-02F061DD-144F-4801-AA50-2D3713561FB9Q34959822-3A7749F9-7D6C-4D5B-861E-A1B773C802B5Q35536242-41BE3AB4-5520-4BCD-8BC2-54C97F65AE1EQ35682575-CE0AB359-2774-4668-8EAF-142975B4E0A3Q36241389-0B36AAA0-9859-40D5-968C-FB32C9878EA9Q36531658-DA1BC7E1-D362-4E9D-8738-1427A2494C9FQ36736060-4A50DFCD-2E5C-493E-B868-A03BCFA6A5C6Q36764001-81CD5AF1-EF6D-4BF6-B67A-142CCD447135Q36916924-BF4B458A-C85D-4593-9B69-6418FDAC8A41Q37004031-3E88F776-0F41-4DC7-9D70-26BC8C6A90D2Q37114565-FB5E2E63-D06B-44B0-B87F-583407CF874AQ37156956-EED230C7-FFFC-4A08-994E-2486AB96E373Q37328680-F08827D7-E340-4AA8-BE7F-A477F0C5995DQ37377940-78D11D44-D0B8-425F-A677-8116708321ADQ37383508-2E19DB45-4462-44F9-B92D-134C22576053Q37421521-CA34CC2D-CA19-4FC7-AA1C-9F793BCDCBA0Q37428883-51D2C3AF-85E6-43E7-82A4-2FE5D9208EF1
P2860
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A once-daily, oral, direct Fac ...... is after total hip replacement
@ast
A once-daily, oral, direct Fac ...... is after total hip replacement
@en
A once-daily, oral, direct Fac ...... is after total hip replacement
@nl
type
label
A once-daily, oral, direct Fac ...... is after total hip replacement
@ast
A once-daily, oral, direct Fac ...... is after total hip replacement
@en
A once-daily, oral, direct Fac ...... is after total hip replacement
@nl
prefLabel
A once-daily, oral, direct Fac ...... is after total hip replacement
@ast
A once-daily, oral, direct Fac ...... is after total hip replacement
@en
A once-daily, oral, direct Fac ...... is after total hip replacement
@nl
P2093
P3181
P1433
P1476
A once-daily, oral, direct Fac ...... is after total hip replacement
@en
P2093
Ajay K Kakkar
Bengt I Eriksson
Christoph Dierig
Eva Muehlhofer
Frank Misselwitz
Menno V Huisman
ODIXa-HIP Study Investigators
Ola E Dahl
Peter Kälebo
Sylvia Haas
P304
P3181
P356
10.1161/CIRCULATIONAHA.106.642074
P407
P577
2006-11-20T00:00:00Z